Gornitzky & Co. represented the underwriters, led by Wells Fargo, in RedHill Biopharma’s USD 14.4 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).
Wells Fargo Securities acted as lead book-running manager and Roth Capital Partners acted as joint book-running manager for the offering. MLV & Co acted as co-manager for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.